Voyager Therapeutics (NASDAQ: VYGR) disclosed that President and CEO Alfred Sandrock sold 11,511 shares of common stock on April 2, 2026. The shares were transacted at prices between $3.81 and $3.95, producing gross proceeds of $44,547. The company’s share price is trading at $3.96 and the market capitalization stands at $236 million.
The sale was carried out automatically to satisfy tax withholding requirements associated with the vesting of restricted stock units, according to a Form 4 filing with the Securities and Exchange Commission. Following the transaction, Sandrock directly owns 472,549 shares of Voyager Therapeutics.
Public filings and third-party analysis provide additional context on the company’s financial position and valuation. InvestingPro’s assessment indicates the stock appears undervalued when measured against its Fair Value calculations. The same analysis highlights a healthy liquidity position reflected in a current ratio of 7.64. Offsetting those positives, Voyager reported a loss of $2.04 per share over the most recent twelve-month period. For subscribers, a Pro Research Report is available for VYGR among more than 1,400 U.S. equities.
Beyond the insider transaction and balance-sheet metrics, Voyager continues to advance its clinical and preclinical pipeline. H.C. Wainwright reiterated a Buy rating on the company and kept a price target of $25.00, describing 2026 as an important year for anticipated milestones. Enrollment in the VY7523 anti-tau multiple ascending dose study is complete, with initial tau PET imaging data expected in the second half of 2026.
Truist Securities also reaffirmed a Buy rating, pointing to forward movement across Voyager’s central nervous system-focused programs. The VY1706 gene therapy candidate is progressing through GLP toxicology studies, and an investigational new drug filing is scheduled for the second quarter of 2026. Voyager has set a goal of first-in-human dosing for VY1706 in the second half of 2026.
These corporate developments - insider tax-related selling, a strong current ratio, an extended trailing loss per share, and reiterated analyst Buy ratings tied to upcoming clinical readouts - together frame the near-term narrative for Voyager. The company’s research activities and forthcoming data milestones are central to how investors and analysts are positioning around the stock as the year unfolds.